Peripheral artery disease, biomarkers, and darapladib

American Heart Journal

Volumn 161, Issue 5, 2011, Pages 972-978

  Berger, Jeffrey S ^a,b   Ballantyne, Christie M ^c   Davidson, Michael H ^d   Johnson, Joel L ^e   Tarka, Elizabeth A ^e,f   Lawrence, Denise ^g   Trivedi, Trupti ^e,f   Zalewski, Andrew ^d,e,f,g   Mohler III, Emile R ^b,g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e GLAXOSMITHKLINE   (United States)

^f 4th Floor Penn Tower Building ^*

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; DARAPLADIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; OSTEOPROTEGERIN; PADGEM PROTEIN; PHOSPHOLIPASE A2; PLACEBO; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EXPLORATORY RESEARCH; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BENZALDEHYDES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OXIMES; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955884904     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.01.017     Document Type: Article

References (34)

1. L. Norgren, W.R. Hiatt, and J.A. Dormandy Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) J Vasc Surg 45 Suppl S 2007 S5 67
2. E.R. Mohler III Peripheral arterial disease: identification and implications Arch Intern Med 163 2003 2306 2314
3. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation Circulation 113 2006 e463 654
4. R.D. Rosenberg, and W.C. Aird Vascular-bed-specific hemostasis and hypercoagulable states N Engl J Med 340 1999 1555 1564
5. E. Mohler III, and J. Giri Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines Curr Med Res Opin 24 2008 2509 2522
6. E.R. Mohler III Therapy insight: peripheral arterial disease and diabetes-from pathogenesis to treatment guidelines Nat Clin Pract Cardiovasc Med 4 2007 151 162 (Pubitemid 46370397)
7. P.M. Ridker C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease Clin Chem 55 2009 209 215
8. J.P. Cooke, and A.M. Wilson Biomarkers of peripheral arterial disease J Am Coll Cardiol 55 2010 2017 2023
9. J.S. Berger, J.L. Petersen, and D.L. Brown Vascular disease burden and in-hospital outcomes among patients undergoing percutaneous coronary intervention in New York State Circ Cardiovasc Interv 2 2009 317 322
10. M.J. Alberts, D.L. Bhatt, and J.L. Mas Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry Eur Heart J 30 2009 2318 2326
11. P.G. Steg, D.L. Bhatt, and P.W. Wilson One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 2007 1197 1206 (Pubitemid 46465728)
12. 2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study J Am Coll Cardiol 51 2008 1632 1641 (Pubitemid 351635837)
13. 2 reduces complex coronary atherosclerotic plaque development Nat Med 14 2008 1059 1066
14. R.C. Hoogeveen, A. Morrison, and E. Boerwinkle Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study Atherosclerosis 183 2005 301 307 (Pubitemid 41579281)
15. Y. Iwashima, T. Horio, and Y. Suzuki Adiponectin and inflammatory markers in peripheral arterial occlusive disease Atherosclerosis 188 2006 384 390 (Pubitemid 44301128)
16. P.M. Ridker, M.J. Stampfer, and N. Rifai Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease JAMA 285 2001 2481 2485 (Pubitemid 32433842)
17. I. Tzoulaki, G.D. Murray, and A.J. Lee C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study Circulation 112 2005 976 983 (Pubitemid 41170265)
18. V. Aboyans, M.H. Criqui, and J.O. Denenberg Risk factors for progression of peripheral arterial disease in large and small vessels Circulation 113 2006 2623 2629 (Pubitemid 43948011)
19. S.E. Musicant, L.M. Taylor Jr., and D. Peters Prospective evaluation of the relationship between C-reactive protein, d-dimer and progression of peripheral arterial disease J Vasc Surg 43 2006 772 780 [discussion 780]
20. A. Shankar, J. Li, and F.J. Nieto Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension Am Heart J 154 2007 495 501 (Pubitemid 47268244)
21. G. Brevetti, V. Schiano, and E. Laurenzano Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease Eur Heart J 29 2008 224 230 (Pubitemid 351164877)
22. A.D. Pradhan, N. Rifai, and P.M. Ridker Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men Circulation 106 2002 820 825
23. A.D. Blann, K.T. Tan, and M.H. Tayebjee Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty Thromb Haemost 93 2005 578 583 (Pubitemid 40392550)
24. B. Dieplinger, M. Haltmayer, and W. Poelz Value of adiponectin as predictor of 5-year all-cause mortality in patients with symptomatic peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) study Clin Chim Acta 408 2009 87 91
25. B. Dieplinger, W. Poelz, and M. Haltmayer Association of adiponectin and amino terminal proBNP in peripheral arterial disease Clin Chim Acta 377 2007 192 197 (Pubitemid 44908250)
26. H. Komai, R. Shibata, and M. Juri Plasma adiponectin as a predictive factor of survival after a bypass operation for peripheral arterial disease J Vasc Surg 50 2009 95 99
27. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
28. M.H. Davidson Clinical significance of statin pleiotropic effects: hypotheses versus evidence Circulation 111 2005 2280 2281 (Pubitemid 40647061)
29. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
30. Braun L.T., and Davidson M.H. Lp-PLA2: a new target for statin therapy Curr Atheroscler Rep 12 2010 29 33
31. Thompson A., Gao P., and Orfei L. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
32. 2: a new kid on the block Clin Chem 52 2006 1645 1650 (Pubitemid 44330696)
33. A.T. Hirsch, M.H. Criqui, and D. Treat-Jacobson Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 2001 1317 1324 (Pubitemid 33015522)
34. A.T. Hirsch, T.P. Murphy, and M.B. Lovell Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey Circulation 116 2007 2086 2094 (Pubitemid 350023753)